Evaluation of Hand Strength and Spasticity in Hemiplegic Patients

Sponsor
Afyonkarahisar Health Sciences University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05662878
Collaborator
(none)
300
1
7.5
40.2

Study Details

Study Description

Brief Summary

The aim in this study is to evaluate spasticity and hand grip strength with a finger hand robot in the Turkish population.

Condition or Disease Intervention/Treatment Phase
  • Other: Assessment of Hand Strength and Spasticity

Detailed Description

Spasticity has been defined as "irregular sensorimotor control resulting from upper motor neuron lesion manifesting as intermittent or sustained involuntary activation of muscles".

The commonly used tools in the evaluation of spasticity are subjective clinical scales, including Ashworth Scale (AS), Modified AS (MAS), Tardieu Scale (TS), Modified TS (MTS), and Tone Assessment Scale (TAS). Current scales are based on the clinician's perception of the patient assessing spasticity through their perceptions, experience, and training over the years. An objective measure of spasticity is required, and the development of robot-based systems for this purpose can help clinicians objectify their assessment.

It has been widely shown that robotic systems can be useful in the rehabilitation of adults and children with brain damage. In addition, these systems can be used to assess upper extremity function during treatment.

The aim in this study is to evaluate spasticity and hand grip strength with a finger hand robot in the Turkish population.

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Evaluation of Hand Strength and Spasticity in Hemiplegic Patients Using Hand-Finger Robot Device
Actual Study Start Date :
Oct 15, 2022
Anticipated Primary Completion Date :
Feb 20, 2023
Anticipated Study Completion Date :
May 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Patient Group

Hemiplegic Patients

Other: Assessment of Hand Strength and Spasticity
Assessment of Hand Strength and Spasticity

Control Group

Healthy Individuals

Other: Assessment of Hand Strength and Spasticity
Assessment of Hand Strength and Spasticity

Outcome Measures

Primary Outcome Measures

  1. Neurophysiological Evaluation [2022.12-2023.1]

    Brunnstrom Staging is a test that evaluates the motor development of hemiplegic patients. In this test, the neurophysiological recovery process of the hemiplegic patient was defined as 6 stages. According to this staging, the lowest stage; stage 1 (flask, the stage without voluntary movement), the highest stage was determined as stage 6 (stage with isolated joint movement). In Brunnstrom staging, the hand, upper extremity, and lower extremity are evaluated separately.

  2. Muscle Power Assessment (MRC Scale) [2022.12-2023.1]

    The MRC is a scale for muscle strength that ranges from 0 to 5, relative to the maximum expected for a given muscle.

  3. Spasticity Evaluation [2022.12-2023.1]

    It was planned to evaluate spasticity with the Modified Ashworth Scale (MAS). In MAS, patients are evaluated over 4 points. 0; there is no increase in muscle tone, and 4 indicates that the extremity is rigid in flexion and extension.

  4. The Fugl-Meyer Assessment for Upper Extremity (FMA-UE) [2022.12-2023.1]

    The Fugl-Meyer Assessment Scale was developed to quantitatively evaluate sensorimotor recovery after stroke. It is based on Brunnstrom motor recovery stages. Turkish validity and reliability study was conducted.

  5. Hand and Finger Grip Strength Assessment [2022.12-2023.1]

    Grip strength will be evaluated with the Jamar hydraulic hand dynamometer. Patients will be asked to squeeze with maximum force and each measurement will be made three times, and their averages will be recorded in kg. Finger grip strength will be evaluated with the "Jamar Digital Pinchmeter". Patients will be placed in the sitting position with the wrist in 90° flexion and the forearm in the neutral position. Measurements will be made bilaterally in three different positions as lateral, palmar and fingertip grips. Patients will be asked to squeeze with maximum force and each measurement will be made three times, and their averages will be recorded in kg. The dynamometer has a dual scale readout which displays isometric grip force from 0-90 kg. Higher scores means better grip strength.

  6. Assessment with Amadeo Device [2022.12-2023.1]

    Amadeo (Tyromotion, Graz, Austria) is an end-effector device designed for the hand and is one of the very few options currently available on the commercial market. It is a device that is attached to the forearm with its groove-shaped structure and to the fingers with the support of magnets using bandages. The device performs flexion and extension movements of the fingers. It moves the fingers of the patients in the patterns defined in the software of the device. It provides training with passive, assistive and active movements that are ideal for use in all phases of neurological rehabilitation. It was planned to measure finger ROM, muscle strength and spasticity with Amadeo device.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Hemiplegic patients with sufficient cognitive and language skills to follow instructions will be included in the study.
Exclusion Criteria:
  • Uncooperative Patient

  • Having a skin ulcer on the hand,

  • Patients with contractures of the hand fingers will be excluded.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Afyonkarahisar Health Sciences University Afyonkarahisar Turkey 03200

Sponsors and Collaborators

  • Afyonkarahisar Health Sciences University

Investigators

  • Principal Investigator: Sevda ADAR, MD, Afyonkarahisar Health Sciences University
  • Principal Investigator: Ali İzzet AKÇİN, MD, Afyonkarahisar Health Sciences University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Sevda Adar, Principal Investigator, Afyonkarahisar Health Sciences University
ClinicalTrials.gov Identifier:
NCT05662878
Other Study ID Numbers:
  • HemiHFR22
First Posted:
Dec 23, 2022
Last Update Posted:
Dec 27, 2022
Last Verified:
Dec 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Sevda Adar, Principal Investigator, Afyonkarahisar Health Sciences University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 27, 2022